Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Hautklinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Publikationen
Ergebnisse pro Seite:  10

Berberich-Siebelt, F.; Vaeth, M.; Schliesser, U. et al.

The dependence on NFAT levels discriminates conventional T cells from Foxp3(+) regulatory T cells

IMMUNOLOGY. Bd. 137. 2012 S. 416-416


Poppelreuther, M; Rudolph, B; Du, C et al.

The N-terminal region of acyl-CoA synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake

JOURNAL OF LIPID RESEARCH. Bd. 53. H. 5. 2012 S. 888-900


Zuberbier, T.; Aberer, W.; Brockow, K. et al.

Therapy of urticaria: German language version of the international S3-guideline

ALLERGOLOGIE. Bd. 35. H. 4. 2012 S. 187-208


Daut, V.; Staubach, P.; Hoermann, K. et al.

Urticaria. Basic knowledge for the ENT specialist

HNO. Bd. 60. H. 5. 2012 S. 457-465


Karbach, S; Croxford, A; Oelze, M et al.

Vascular dysfunction and skin inflammation are mechanistically interconnected by IL17A and IL-6 signaling in a mouse model of psoriasis

EUROPEAN HEART JOURNAL. Bd. 33. 2012 S. 277-277


Bork, K

WAO Guideline for the Management of Hereditary Angioedema

World Allgery Organ J. Bd. 5. H. 12. 2012 S. 182-199


Hofmann, C; Vieths, S; Scheurer, S et al.

A novel method for flow cytometry-based analysis of T cell cross reactivity of birch pollen allergen Bet v 1 and homologous food allergens

EXPERIMENTAL DERMATOLOGY. Bd. 20. H. 2. 2011 S. 164-164


Bork, K; Wulff, K; Meinke, P et al.

A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor

CLINICAL IMMUNOLOGY. Bd. 141. H. 1. 2011 S. 31-35


Fischer, MR; Lorenz, B; Jonuleit, H et al.

A PBMC-transfer model to analyze human cutaneous leishmaniasis - suitability analysis of various immunodeficient mice

EXPERIMENTAL DERMATOLOGY. Bd. 20. H. 2. 2011 S. 190-190


O'Day, S; Pavlick, A; Loquai, C et al.

A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

BRITISH JOURNAL OF CANCER. Bd. 105. H. 3. 2011 S. 346-352